Revolutionizing Drug Delivery: A Patient-Centric Approach
A groundbreaking study by a doctoral researcher at the University of Cincinnati, United States, has sparked a paradigm shift in the pharmaceutical industry. Precious Akinnusi advocates for patient-centered therapies, emphasizing that the effectiveness of drugs is directly tied to treatment designs that seamlessly integrate into patients' daily lives.
In an exclusive interview with Sunday PUNCH, Akinnusi revealed his research focus on biomaterials-based drug delivery systems, prioritizing patient comfort and convenience. He believes that understanding daily routines is crucial for designing treatments that don't burden patients with complex regimens.
"Instead of asking patients to adapt to intricate therapies, my research explores how drug delivery systems can become an integral part of their everyday lives," Akinnusi explained. His work primarily targets the skin, aiming to develop localized treatment systems for conditions like skin cancer. By concentrating therapy at the disease site, he aims to minimize side effects while maximizing effectiveness.
Akinnusi's innovative approach also explores the skin as a gateway to systemic circulation, offering an alternative to injections or oral medications for certain treatments. He highlights the importance of not just identifying drugs but ensuring their delivery systems are patient-friendly and effective.
"The success of a drug goes beyond its discovery. If the delivery method doesn't suit the patient, the science falls short of its potential," Akinnusi stated. His transition from drug discovery to drug delivery reflects a natural progression in his research, driven by a patient-centric philosophy.
Akinnusi's background as a biochemist at Adekunle Ajasin University, Ondo State, laid the foundation for his research. His early studies focused on identifying bioactive molecules from plants and understanding their interactions with disease pathways, utilizing biochemical analysis and computational tools.
One notable study examined anthocyanins and their interactions with SARS-CoV-2 proteins during the COVID-19 pandemic. Akinnusi's research challenged the initial focus on single targets, recognizing the virus's dynamic nature. He explored how individual compounds performed across various viral mechanisms, identifying stable binders like cyanidin 3-O-glucosyl-rutinoside, which demonstrated consistent interactions with multiple proteins.
This patient-centric approach to drug delivery has the potential to revolutionize healthcare, ensuring treatments are not only effective but also patient-friendly and accessible.
